M
Markus Grompe
Researcher at Oregon Health & Science University
Publications - 323
Citations - 37404
Markus Grompe is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Fanconi anemia & Stem cell. The author has an hindex of 88, co-authored 313 publications receiving 34220 citations. Previous affiliations of Markus Grompe include Northwestern University & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Therapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes
Anne Vonada,Amita Tiyaboonchai,Sean Nygaard,Jeffrey Posey,Alexander Mack Peters,Shelley R. Winn,Alessio Cantore,Luigi Naldini,Cary O. Harding,Markus Grompe +9 more
TL;DR: In this article, the authors developed a method to expand hepatocytes bearing therapeutic transgenes, which achieved therapeutic thresholds in hemophilia B and phenylketonuria in neonatal mice.
Journal ArticleDOI
Response to "Can 'humanized' mice improve drug development in the 21st century?".
TL;DR: The opinion article entitled “Can ‘humanized’ mice improve drug development in the 21st century?” contains some factual errors regarding properties of the FRG liver humanization model that the author does not have any direct experience with the model.
Journal ArticleDOI
Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model
Qing Shuo Zhang,Matthew Deater,Ngoc Phan,Andrea N. Marcogliese,Angela Major,Eva C. Guinan,Markus Grompe +6 more
TL;DR: Fanconi anemia is an inherited bone marrow failure disorder associated with a high incidence of leukemia and solid tumors and currently, no interventions to prevent or delay the formation of solid tumors are available.
Journal ArticleDOI
A Therapy for Liver Failure Found in the JNK Yard
Holger Willenbring,Markus Grompe +1 more
TL;DR: A potentially druggable target is identified that enhances hepatocyte proliferation and promotes liver regeneration, thereby preventing liver failure and preventing chronic liver failure.
Journal ArticleDOI
Transition of stem cells to therapeutically functional tissue-specific cells.
TL;DR: The transition of hematopoietic stem cells to hepatocytes is much too slow and much too inefficient to be of any clinical use without further improvement of the system, and some important goals for stem cell research aimed at tissue repair are suggested.